Jacques Galipeau, MD, FRCP(C)

Adjunct Professor, Hematology and Medical Oncology, Pediatrics & Medicine

Emory University School of Medicine


A Georgia Cancer Coalition Distinguished Cancer Scholar, Dr. Jacques Galipeau is Adjunct Professor of Hematology and Medical Oncology, Pediatrics & Medicine at Emory University School of Medicine. He was Co-Director of the Winship Cancer Institute Tumor Immunology-Immunotherapy initiative as well as Director of the Emory Personalized Immunotherapy Center (EPIC).

Dr. Galipeau obtained his Medical Degree from the University of Montreal in 1988 and completed specialty training in internal medicine at the McGill-affiliated Jewish General Hospital. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology and Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children's research hospital in Memphis, Tennessee. In his 12 year career at McGill University starting in 1997, he initiated and developed a research program in cell and immunotherapy of catastrophic illnesses including cancer, immune and cardiovascular disease. The development of regenerative medicine and innovative cell-based therapies are on-going research and development interests pursued at Emory University since October 2009.


Since 1997, Dr. Galipeau has initiated and developed a research program in cell and gene therapy of catastrophic illnesses including cancer, immune and cardiovascular disease. The goal of Dr. Galipeau's research is to continue the development of a remarkable new class of biological agents we invented: the GIFT fusokines. These are in essence fusion proteins borne of GMCSF (at the N-terminus) and interleukins (at the C-terminus) whose acquired immunobiological properties render them extremely attractive as a novel biopharmaceutical strategy to treat cancer. Dr. Galipeau's team is studying the use of GIFT21 in vitro, in mouse models of cancer and in human cells.

As co-Director for the Tumor Immunology Immunotherapy Program within the Winship Cancer Institute, Dr. Galipeau's mandate was to develop and implement innovative trans-disciplinary translational (bench to bedside) research in cell-based and biological therapeutics and Tumor Immunotherapy. He has benefited from continuous operational funding from the Canadian Institute for Health Research (The Canadian equivalent of NIH) since 1998. He was recently granted a Georgia Cancer Coalition Distinguished Cancer Clinician and Scientist Award.


As Dr. Galipeau's publication record shows, he has created a line of investigation which seeks to investigate and develop the use of cell therapy to alter the immune response and has published numerous peer-reviewed manuscripts spanning cell biochemistry, physiology, immunology, genetic engineering and cell therapy translational use in pre-clinical disease models. Dr. Galipeau has extensive experience collaborating with multidisciplinary scientists, specifically in the areas of biology and translational medicine.